Evidence map›Paper›PMID 23950724›Full record

ArticlePLoS genetics2013

Re-ranking sequencing variants in the post-GWAS era for accurate causal variant identification.

Laura L Faye, Mitchell J Machiela, Peter Kraft, Shelley B Bull, Lei Sun

Abstract read
In one paragraph

Article in PLoS genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. A review of post-GWAS studies in schizophrenia.Translational psychiatry · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura L FayeDivision of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Mitchell J Machiela
Peter Kraft
Shelley B Bull
Lei Sun

Funding

Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098216 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI RIBOLI, ELIO · 2003 to 2011
$7.4M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
Joint Interdisciplinary Training Program in Biostatistics & Computational BiologyT32GM074897 · NIGMS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUTTENHOWER, CURTIS, LIN, XIHONG · 2005 to 2019
$3.7M
CIHR 84287-1CIHR 84287-2CIHR GET-101831CIHR MDR-88001CIHR MOP-84287NCI NIH HHS U01 CA098216NCI NIH HHS U01 CA098233NCI NIH HHS U01 CA098710NCI NIH HHS U01-CA98216NCI NIH HHS U01-CA98233NCI NIH HHS U01-CA98710NIGMS NIH HHS T32 GM074897NIGMS NIH HHS T32-GM074897Wellcome TrustWellcome Trust 076113
6 · The paper itself

Abstract

Next generation sequencing has dramatically increased our ability to localize disease-causing variants by providing base-pair level information at costs increasingly feasible for the large sample sizes required to detect complex-trait associations. Yet, identification of causal variants within an established region of association remains a challenge. Counter-intuitively, certain factors that increase power to detect an associated region can decrease power to localize the causal variant. First, combining GWAS with imputation or low coverage sequencing to achieve the large sample sizes required for high power can have the unintended effect of producing differential genotyping error among SNPs. This tends to bias the relative evidence for association toward better genotyped SNPs. Second, re-use of GWAS data for fine-mapping exploits previous findings to ensure genome-wide significance in GWAS-associated regions. However, using GWAS findings to inform fine-mapping analysis can bias evidence away from the causal SNP toward the tag SNP and SNPs in high LD with the tag. Together these factors can reduce power to localize the causal SNP by more than half. Other strategies commonly employed to increase power to detect association, namely increasing sample size and using higher density genotyping arrays, can, in certain common scenarios, actually exacerbate these effects and further decrease power to localize causal variants. We develop a re-ranking procedure that accounts for these adverse effects and substantially improves the accuracy of causal SNP identification, often doubling the probability that the causal SNP is top-ranked. Application to the NCI BPC3 aggressive prostate cancer GWAS with imputation meta-analysis identified a new top SNP at 2 of 3 associated loci and several additional possible causal SNPs at these loci that may have otherwise been overlooked. This method is simple to implement using R scripts provided on the author's website.

Indexed as

Models, TheoreticalBreast NeoplasmsFemaleGenome-Wide Association StudyGenotypeHigh-Throughput Nucleotide SequencingHumansMalePolymorphism, Single NucleotideProstatic NeoplasmsSample Size

Identifiers

PMID23950724
PMCPMC3738448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.